Immunogenic and vaccine compositions against SARS-CoV-2

Patent metadata

Field	Value
Publication number	US-12150985-B2
Application number	US-202217804954-A
Country	US
Kind code	B2
Filing date	Jun 1, 2022
Priority date	Mar 5, 2020
Publication date	Nov 26, 2024
Grant date	Nov 26, 2024

Abstract

Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe Acute Respiratory Syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.

First claim

What is claimed is:

1. A method of preventing or delaying the onset of COVID-19 or of reducing at least one symptom of COVID-19 in a subject, comprising the step of providing an effective amount of an immunogenic composition comprising a receptor-binding domain (RBD) polypeptide, wherein the RBD polypeptide is amino acid residues 333-528 of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, wherein the numbering of the amino acid residues corresponds to SEQ ID NO: 2, and a carrier to the subject.

2. The method of claim 1 , wherein the composition is provided to the subject once.

3. The method of claim 1 , wherein the composition is provided to the subject more than once.

4. The method of claim 3 , wherein the composition is provided subsequently to the subject within weeks, months, or years of the providing step.

5. The method of claim 1 , wherein the subject displays one or more symptoms of COVID-19.

6. The method of claim 1 , wherein the subject lacks any symptoms of COVID-19.

7. The method of claim 1 , wherein the subject has been exposed to COVID-19.

8. The method of claim 1 , wherein the subject has come into contact with a subject that has COVID-19.

9. The method of claim 1 , wherein the subject is a child, an elderly person, exposed to a bioweapon or at risk thereof, is a member of the military, or is a health care worker.

10. The method of claim 1 , wherein said RBD polypeptide is the amino acid sequence of SEQ ID NO: 45.

11. The method of claim 1 , wherein said RBD polypeptide comprises the receptor binding motif (RBM) of SEQ ID NO: 4.

12. The method of claim 1 , wherein said RBD polypeptide includes the amino acid sequence of one or more of SEQ ID NOs: 8-32 and 34-41.

13. The method of claim 1 , wherein said RBD polypeptide includes the amino acid sequence of one or more of SEQ ID NOs: 9, 13, 14, 16, 18, 20, 25, 27, 32, 35, 36, 37, 39, and/or 40.

Assignees

• Univ Iowa State Res Found Inc
• Lowa State Univ Research Foundation Inc

Inventors

• Cho Michael Wan

Classifications

• C07K14/165

  Coronaviridae, e.g. avian infectious bronchitis virus · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• C07K14/001

  by chemical synthesis · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/55583

  Polysaccharides · CPC title